COMPASS Pathways

Compass Pathways Plc functions as an investment holding company. It operates through its subsidiaries which provide mental health care services. The company was founded by Goldsmith George Jay and Malievaskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

COMPASS Pathways reports Q4 earnings, faces challenges, explores opportunities

COMPASS Pathways showcased progress in its clinical programs, financial performance, and strategic initiatives. Despite challenges in trial protocols and financial losses, the company remains focused on advancing its treatment options and exploring growth opportunities.

COMPASS Pathways advances Phase 3 TRD program amidst financial challenges

COMPASS Pathways is making progress in their Phase 3 TRD program and maintaining a strong financial position for future developments.
Acceptance of new CPT codes and engagement with health systems present growth opportunities for the company.
However, challenges like financial losses, mixed views on commercialization, and operational differences exist.
Overall, COMPASS Pathways is strategically positioned to capitalize on the evolving landscape of psychedelic therapies.

COMPASS Pathways progresses in trials amidst market challenges and opportunities

COMPASS Pathways is advancing well in trials for treatment-resistant depression and strengthening its market position through IP protection and regulatory milestones.
Challenges lie in differentiation from competitors and establishing unique value propositions, but opportunities exist in FDA support, market growth, and funding flexibility.
Overall, the company's performance, financial stability, and strategic moves position it favorably in the evolving landscape of psychedelic therapies.

COMPASS Pathways reports strong Q3 earnings, eyes transformative 2024

COMPASS Pathways demonstrated robust financial performance in Q3 2023, with strong cash reserves and a strategic private placement financing, positioning the company well for upcoming milestones.
While facing challenges in patient recruitment and trial complexities, COMPASS is leveraging AI models and expanding clinical sites to optimize operations and drive therapeutic innovation.
With Phase III data on the horizon and ongoing advancements in research and development, COMPASS Pathways is poised for a transformative year in 2024, capitalizing on growth opportunities and research insights.

COMPASS Pathways advances COMP360 trials amid financial challenges

COMPASS Pathways' financials show investment in research and development despite net losses, with a strong cash position.
Progress in key trials for COMP360 in TRD and positive safety data indicate promising developments in mental health treatment.
Challenges in enrollment, delays in data, and regulatory monitoring require strategic navigation for future success.
Opportunities lie in collaborations, potential indications, and a focused approach to TRD treatment with COMP360.

COMPASS Pathways advances in clinical trials and strategic partnerships

COMPASS Pathways showcased strong clinical and financial performance in Q1 2024 earnings call, emphasizing progress in Phase III trials and positive PTSD study results
While facing challenges in risk mitigation and therapy comparisons, the company's strategic collaborations and upcoming data releases offer promising opportunities for growth

Compass Pathways faces trial delays, strengthens leadership for commercial success

Compass Pathways navigates delays in pivotal trials while focusing on data disclosure and commercial readiness. New leadership strengthens strategic direction and commercial landscape. Challenges include trial complexities and managing attrition rates, with opportunities in leveraging Phase III data and commercial collaborations.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Compass Pathways Plc is an investment holding company. It operates through its subsidiaries which provide mental health care services. The company was founded by Goldsmith George Jay and Malievaskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

COMPASS Pathways partners with One Mind to fund Rising Star Awards for the next generation of mental health researchers

Adobe

Atai Life Sciences BV

Cybin

Delta Air Lines

GW Pharmaceuticals

Home Depot

Johnson & Johnson

JPMorgan Chase & Co

Lowe's

Mind Medicine MindMed

Netflix

PayPal

Twitter

Wells Fargo

Walmart

Interested in Investing in Psychedelics? Check Out This Podcast.

LONDON, April 04, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that members of its management team will present at the 21st Annual Needham Virtual Healthcare Conference at 2:15pm ET on 14 April 2022.

COMPASS Pathways to participate in Needham Healthcare conference

Pioneering c ollaboration with King's College London and South London and Maudsley NHS Foundation Trust

COMPASS Pathways and partners launch The Centre for Mental Health Research and Innovation, in the UK

COMPASS Pathways plc (CMPS) CEO George Goldsmith on Q4 2021 Results - Earnings Call Transcript

LONDON, United Kingdom, Feb. 24, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the fourth quarter and full year 2021 and gave an update on recent progress across its business.

COMPASS Pathways announces financial results for the fourth quarter and full year 2021 and business highlights

LONDON, United Kingdom, Feb. 17, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the fourth quarter and full year 2021, and provide an update on recent business developments on 24 February 2022.

COMPASS Pathways plc to announce fourth quarter and full year 2021 financial results on 24 February 2022

Biotech and pharmaceutical companies are generally involved in the lengthy process of getting their drug candidates to market through clinical trials.

5 Psychedelic Therapeutics Decisions Coming in 2022

London, UK and New York, US, 19 January 2022

Two thirds of physicians surveyed believe psilocybin therapy has potential benefit for patients with treatment-resistant depression

LONDON, Jan. 10, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in a fireside chat at the H.C. Wainwright BioConnect Virtual Conference, available on demand from 10 to 13 January.

COMPASS Pathways to participate in H.C. Wainwright investor conference

Study demonstrates feasibility of simultaneous administration of COMP360 psilocybin  in a controlled setting to healthy participants with 1:1 therapist support

COMP360 psilocybin study of 89 healthy participants published in Journal of Psychopharmacology

Field Trip Health Ltd

Psychedelic substances are often grouped together with cannabis, but there are some important distinctions. ATAI, CMPS and FTRP are some of the best stocks in the space.

3 Psychedelic Stocks to Play the Shroom Boom

Psilocybin-focused mental health care company COMPASS Pathways plc (NASDAQ:CMPS) revealed Friday that it has been selected for addition to the Nasdaq Biotechnology Index (NASDAQ:NBI), effective as of market open on Monday, Dec. 20. “We are proud to announce our addition to the esteemed Nasdaq Biotechnology Index,” George Goldsmith, CEO and founder of Compass Pathways said.

Psychedelics Company COMPASS Pathways To Join NASDAQ Biotechnology Index

London, U.K., Dec. 17, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced it has been selected for addition to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective as of market open on Monday, December 20, 2021. The NBI is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (Nasdaq®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).  For this year's annual reconstitution, 120 securities will be added to the Index and 16 will be removed.

COMPASS Selected for Addition to NASDAQ Biotechnology Index

M atthew Owen s appointed General Counsel and Chief Legal Officer ;

COMPASS Pathways announces changes in Executive Team

Psilocybin-focused mental health care company COMPASS Pathways plc (NASDAQ:CMPS) announced Monday it had achieved positive results from its exploratory study of COMP360 psilocybin therapy in conjunction with SSRI use. SSRI, or selective serotonin reuptake inhibitors, are the most commonly prescribed antidepressants.

Psilocybin Therapy Combined With SSRI Antidepressants Is Possible, COMPASS Study Confirms

COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in open-label treatment-resistant depression study

Ameri Holdings

GH Research PLC

Jaguar Health

Seelos Therapeutics

The usage of psychedelics like psilocybin, LSD, ketamine, and others are becoming more mainstream, especially with the initial steps to legalization getting moving across a number of states in the U.S. As a result, the psychedelics market is projected to grow 12.4% annually, reaching $10.75 billion in 2027.

9 Psychedelic Stocks to Watch For 2022

Michael Falvey joins COMPASS Pathways as Chief Financial Officer

As COMPASS Pathways (NASDAQ: CMPS) crunches more data from a recent trial investigating psilocybin therapy for treatment-resistant depression (TRD), findings show that a higher dose of 25mg (compared to 1mg and 10mg) occasioned an increase in positive feelings of interest in life and a decrease in negative feelings of distress and fear. COMPASS' phase IIb clinical trial results are a product of the company's focus since 2018 when it received FDA “breakthrough therapy” designation for its COMP360 psilocybin treatments for TRD.

COMPASS Pathways: Positive Psilocybin Trial, High-Dose Group Improves Beyond Depression Reduction

- Positive topline results validated by additional analyses

COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression

LONDON, Nov. 30, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in three investor conferences as follows:

COMPASS Pathways to participate in upcoming Evercore, H.C. Wainwright & Berenberg investor conferences

Biopharmaceutical conglomerate ATAI Life Sciences (NASDAQ:ATAI), a Peter Thiel-backed psychedelic startup that currently has 10 psychedelic programs in the works, has upped its stake in Compass Pathways (NASDAQ:CMPS), a drug developer looking to accelerate patient access to psilocybin therapy for treatment-resistant depression. In recent days, Atai Life Sciences (Compass' biggest shareholder) increased its ownership in Compass Pathways buying another 619,095 shares, taking its stake in the company from 19.4 to 20.8 percent.

Peter Thiel-Backed Psychedelic Start-Up, ATAI Life Sciences, Increases Stake In Compass Pathways

Atai Life Sciences, the Peter Thiel-backed psychedelic start-up, has increased its stake in Compass Pathways.

Peter Thiel-backed psychedelic start-up increases stake in Compass Pathways

The biotech was priced for perfection; its data wasn't.

News for COMPASS Pathways Stock (CMPS)